VTVT stock forecast, quote, news & analysis
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases... Show more
Why vTv Therapeutics (VTVT) Stock Is Down -28.8% in the Last 30 Days
Key Takeaways
- vTv Therapeutics (VTVT) shares fell roughly 28.8% over the last 30 days, declining from about $30.46 to around $21.70.
- The decline extended a longer downtrend, with the stock down approximately 34% over the trailing three-month period.
- The pullback came despite positive clinical progress, including completion of enrollment in the Phase 3 CATT1 trial and a narrower-than-expected third-quarter loss.
- As a pre-revenue, late-stage biopharmaceutical company, VTVT remains highly sensitive to risk sentiment, cash-burn expectations, and the timeline to its anticipated mid-2027 topline data readout.
- Analysts continue to track the stock closely, with clinical catalysts and balance-sheet strength remaining the central investor focus rather than near-term earnings.
- For additional detail on valuation, results, and forward expectations, explore Price Targets, Earnings, and Forecast pages.
- To see how automated strategies are positioning across the market, explore Trending AI Robots.
vTv Therapeutics (VTVT) Company Overview and Market Position
vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates for diabetes and other chronic diseases. Its lead program is cadisegliatin (TTP399), a liver-selective glucokinase activator being evaluated as a potential first-in-class oral adjunctive therapy to insulin for people with type 1 diabetes. The candidate is designed to reduce hypoglycemia without compromising glycemic control, addressing a substantial unmet medical need in a patient population that has lacked new oral adjunctive treatment options for more than a century.
The company's pivotal Phase 3 CATT1 trial is the primary value driver, with top-line results anticipated in mid-2027. Investors follow VTVT primarily for these clinical milestones and the associated regulatory and commercial opportunity, rather than for near-term revenue, given the company's pre-commercial stage.
vTv Therapeutics (VTVT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, VTVT shares declined approximately 28.8%, falling from a closing level near $30.46 to roughly $21.70. The move was not driven by a single day, but rather reflected a steady grind lower punctuated by sharper declines in early November following the company's third-quarter earnings release.
The short-term move is part of a broader downtrend. Over the trailing three-month period, the stock declined roughly 34%, sliding from the low-to-mid $30s to current levels. The stock has traded within a 52-week range of roughly $20.56 to $44.00, underscoring the elevated volatility typical of clinical-stage biotech names.
What Drove VTVT Stock Price in the Last 30 Days
The recent decline unfolded even as the company reported meaningful clinical progress. In early October, vTv Therapeutics announced the completion of enrollment in its Phase 3 CATT1 study of cadisegliatin, followed by randomization of the first participant in the Phase 2a Hybrid CATT1 pilot study in late October. On November 5, the company reported third-quarter 2026 results, including a net loss of approximately $0.94 per share, narrower than the roughly $1.07 consensus estimate.
Despite these milestones, the shares moved lower, suggesting the decline was driven less by negative company-specific news than by broader factors. Clinical-stage biotech stocks have faced persistent risk-off pressure, and VTVT's longer timeline to a definitive catalyst—topline data not expected until mid-2027—may have weighed on sentiment and encouraged profit-taking following the enrollment milestone. The company's ongoing operating losses and cash-burn profile also remain central considerations for investors, even though management has stated its balance sheet is sufficient to fund operations through the anticipated CATT1 data readout.
What Drove VTVT Stock Performance Over the Last Quarter
The three-month decline reflects a broader repricing of the stock from levels reached earlier in 2026, when the company reported strong first-quarter results boosted by a $20 million upfront payment from an amended licensing agreement with Newsoara Biopharma for its PDE4 inhibitor HPP737. That non-dilutive capital strengthened the balance sheet, lifting cash to about $98.1 million at the end of the first quarter.
As the year progressed, investor focus shifted back to the cadisegliatin program's execution and its extended data timeline. With second-quarter results showing a wider net loss tied to increased Phase 3 spending and cash declining to approximately $86.6 million, the shares drifted lower. The absence of a near-term binary catalyst, combined with small-cap biotech sector weakness, contributed to the multi-month pullback.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's top-performing and most relevant AI trading bots. Tickeron offers hundreds of AI-driven bots that trade thousands of tickers, but only those demonstrating notable performance and current market relevance appear in this section. Each bot operates on distinct strategies, timeframes, and performance metrics, giving traders a way to observe automated approaches across different market conditions. Exploring this page can help investors understand how algorithmic strategies are positioning in real time.
VTVT Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the primary catalyst for VTVT is the progression of the cadisegliatin program toward the anticipated mid-2027 topline readout from the Phase 3 CATT1 trial. Investors will also monitor the Phase 2a Hybrid CATT1 pilot study, which is designed to inform future Phase 3 research in patients using hybrid closed-loop insulin delivery systems.
Financial developments will remain in focus as well, including the company's quarterly cash position, operating expense trajectory, and any additional non-dilutive or dilutive financing decisions. Macroeconomic conditions, small-cap biotech sentiment, and the broader interest-rate environment may continue to influence valuation in the absence of near-term clinical data. Regulatory and competitive developments in the diabetes space are additional factors worth watching, though no specific outcomes should be assumed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for VTVT turns negative, indicating new downward trend
VTVT saw its Momentum Indicator move below the 0 level on October 12, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 75 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for VTVT turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 44 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VTVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for VTVT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where VTVT advanced for three days, in 221 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
VTVT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.057) is normal, around the industry mean (3.498). P/E Ratio (-33.919) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (10.331) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. VTVT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VTVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage pharmaceutical holding company, which focuses on the discovery and development of human therapeutics
Industry Biotechnology